Sign in to continue:

Tuesday, April 28th, 2026

Kinder Morgan, Inc. (KMI) 8-K Filing April 24, 2026: Company Information, Securities, and Exchange Details





Kinder Morgan, Inc. 8-K Regulation FD Disclosure – Detailed Investor Article

Kinder Morgan, Inc. (KMI) – Regulation FD Disclosure: Key Points for Investors

Summary of Key Points in the 8-K Report

  • Form 8-K Filed: Kinder Morgan, Inc. filed a Form 8-K current report on April 24, 2026, with the SEC, indicating an important event for the company.
  • Regulation FD Disclosure: The filing is for Regulation FD (Fair Disclosure), which means KMI is providing material information that is important for all shareholders to access equally.
  • Upcoming Investor Event: KMI announced that its representatives will participate in the Barclays Americas Select Conference on May 5, 2026. They are expected to discuss KMI’s business strategy and outlook at this event.
  • Key Securities Registered:

    • Class P Common Stock – Trading Symbol: KMI (Listed on NYSE)
    • 2.250% Senior Notes due 2027 – Trading Symbol: KMI 27A (Listed on NYSE)
  • Corporate Details:

    • Legal Name: Kinder Morgan, Inc.
    • State of Incorporation: Delaware (DE)
    • Business Address: 1001 Louisiana Street, Suite 1000, Houston, TX 77002
    • Business Phone: 713-369-9000
    • SEC Central Index Key (CIK): 0001506307
  • Emerging Growth Company Status: KMI is not an emerging growth company, meaning it does not benefit from certain reduced regulatory requirements.
  • No Amendment: The filing is not an amendment to a previous submission.

Potential Price-Sensitive Information for Shareholders

  • Participation in Barclays Americas Select Conference:

    KMI’s intent to participate in a major investment conference is significant. These events often include presentations and Q&A sessions with analysts and institutional investors, which can reveal updates on strategic direction, financial outlook, and business performance. Any material announcements or guidance provided during the conference could directly impact KMI’s share price.

    Investors should monitor for any post-conference press releases or presentation materials, as these may contain new details not previously disclosed.
  • Regulation FD Filing:

    Regulation FD filings are specifically designed to ensure all investors receive important information at the same time. The fact that KMI made this filing signals that the company anticipates potentially market-moving disclosures at the upcoming conference or as part of its investor communications.
  • Security Listings:

    The confirmation that both the Class P Common Stock (KMI) and the 2.250% Senior Notes due 2027 (KMI 27A) remain listed and registered on NYSE is relevant for shareholders and fixed income investors. Any changes to these securities, such as redemption, buyback, or refinancing, would be price-sensitive.

Other Important Information for Shareholders

  • No Written Communications, Soliciting Material, or Tender Offers:

    The 8-K explicitly states that the filing is not related to written communications under Rule 425, not soliciting material under Rule 14a-12, and not associated with any pre-commencement tender offers under Rules 14d-2(b) or 13e-4(c). This means there are no merger, acquisition, or takeover proposals disclosed at this time.
  • Compliance and Transparency:

    KMI continues to comply with disclosure obligations, reinforcing its commitment to transparency and maintaining investor confidence.

Conclusion

The most notable aspect of this 8-K filing is Kinder Morgan’s planned participation in the Barclays Americas Select Conference, where management could provide updates on business strategy, financial performance, and outlook. Such events commonly result in new information that can influence analyst coverage, investor sentiment, and share price movements. Investors should be alert for any further disclosures or presentations from KMI during or after the conference.


Disclaimer: This article is based on SEC Form 8-K filings and related official documents. It is intended for informational purposes only and does not constitute investment advice. Shareholders and investors are advised to monitor official company releases and consult with their financial advisors before making investment decisions. Past performance is not indicative of future results.




View KINDER MORGAN, INC. Historical chart here



Sutro Biopharma Annual Report 2023: Business Overview, Risk Factors, and Financial Analysis

Sutro Biopharma, Inc. 2025 Annual Report: Key Insights for I...

   Ad

Join Our Investing Seminar

Limited seats available — Reserve your spot today